IndraLab

Statements

ATXN3 activates ZFYVE9. 2 / 2

| 2

reach

"Thus, a progressive decrease in the MV and GCC thickness in this SD-OCT study was directly associated with an annual worsening of SCA3 symptoms (increase in the SARA score)."

38030858

➶

reach

"Additionally, in an open-label clinical trial, it was demonstrated that subcutaneous IGF-1 treatment in SCA3/MJD patients could increase the SARA score after only 8 months; however, this benefit faded after 10–20 months [68]."

| PMC

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

ATXN3 activates ZFYVE9. 2 / 2

INDRA sources:

Databases

Reading